title: [Correction of bioenergetic processes in small intestine during experimental widespread purulent peritonitis].
abstract: The functional activity of mitochondria of the muscular coat of small intestine (MCSI) has been studied in the normal state and under experimental widespread purulent peritonitis (WPP) conditions. The experiments have been carried out on a group of 55 male rabbits of chinchilla breed. It is established that, as a result of the WPP development, the functional activity of mitochondria in MCSI considerably decreases. The comparative analysis of the efficiency of metabolic drugs cytoflavin and neoton showed advantage of the citoflavin preparation, the administration of which allowed the indices of mitochondria in intact animals to be exceeded on the fifth day of postoperative period. The research results show expediency of a complex treatment of WPP using cytoflavin preparation for the normalization of biological oxidation processes and elimination of enteric insufficiency.
authors.forename: V A
authors.initials: VA
authors.lastname: Kosinets
mesh_terms: D000818:Animals; D001407:Bacillus; D004338:Drug Combinations; D004926:Escherichia coli; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000627:therapeutic use*; D007421:Intestine, Small / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D009130:Muscle, Smooth / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009536:Niacinamide / Q000008:administration & dosage / Q000627:therapeutic use*; D010085:Oxidative Phosphorylation / Q000187:drug effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010725:Phosphocreatine / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*; D013492:Suppuration
chemical_list: D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D010725:Phosphocreatine; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate